(0.56%) 5 156.71 points
(0.33%) 38 802 points
(0.62%) 16 256 points
(1.05%) $78.93
(3.31%) $2.21
(1.20%) $2 336.20
(3.46%) $27.61
(0.41%) $969.25
(-0.17%) $0.927
(-0.57%) $10.81
(-0.28%) $0.795
(-0.03%) $91.42
Quarter results tomorrow
(bmo 2024-05-07)
Expected move: +/- 7.08%
@ $31.40
जारी किया गया: 11 Mar 2024 @ 20:03
वापसी: -21.08%
पिछला सिग्नल: Mar 9 - 00:11
पिछला सिग्नल:
वापसी: -7.29 %
Live Chart Being Loaded With Signals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma...
Stats | |
---|---|
आज की मात्रा | 45 408.00 |
औसत मात्रा | 1.29M |
बाजार मूल्य | 3.07B |
EPS | $-1.030 ( 2024-02-06 ) |
अगली कमाई की तारीख | ( $-0.0600 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.95 |
ATR14 | $0.0990 (0.40%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Hamilton James C | Sell | 6 000 | Common Stock |
2024-03-20 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-19 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-18 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-15 | Lu Hongbo | Sell | 0 | Common Stock |
INSIDER POWER |
---|
15.58 |
Last 100 transactions |
Buy: 963 379 | Sell: 694 332 |
मात्रा सहसंबंध
Arrowhead Pharmaceuticals सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
PRDS | 0.893 |
RDUS | 0.892 |
EYPT | 0.874 |
JAKK | 0.869 |
SSYS | 0.868 |
RLAY | 0.864 |
PLRX | 0.864 |
MDXH | 0.863 |
ATLC | 0.86 |
MCRB | 0.859 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
GMII | -0.885 |
RMRM | -0.871 |
MTSI | -0.87 |
COMT | -0.869 |
MEUSW | -0.861 |
DHC | -0.86 |
ALGM | -0.86 |
SBBP | -0.85 |
VTRU | -0.849 |
BGCP | -0.849 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Arrowhead Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र
Arrowhead Pharmaceuticals वित्तीय
Annual | 2023 |
राजस्व: | $240.74M |
सकल लाभ: | $228.24M (94.81 %) |
EPS: | $-1.920 |
FY | 2023 |
राजस्व: | $240.74M |
सकल लाभ: | $228.24M (94.81 %) |
EPS: | $-1.920 |
FY | 2022 |
राजस्व: | $243.23M |
सकल लाभ: | $232.81M (95.72 %) |
EPS: | $-1.670 |
FY | 2021 |
राजस्व: | $138.29M |
सकल लाभ: | $0.00 (0.00 %) |
EPS: | $-1.360 |
Financial Reports:
No articles found.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं